Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Estradiol valerate/dienogest - Bayer HealthCare Pharmaceutials

Drug Profile

Estradiol valerate/dienogest - Bayer HealthCare Pharmaceutials

Alternative Names: Climodien; Climodiène; Dienogest/estradiol valerate; DNG/E2V; E2V/DNG; Klimodien; Lafamme

Latest Information Update: 18 Feb 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Jenapharm
  • Developer Bayer HealthCare Pharmaceuticals
  • Class Estradiol congeners; Estrenes; Hormonal replacements; Oral contraceptives; Small molecules; Steroids; Testosterone congeners
  • Mechanism of Action Estrogen receptor agonists; Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Menopausal syndrome; Postmenopausal osteoporosis
  • No development reported Acne
  • Discontinued Pregnancy

Most Recent Events

  • 18 Feb 2019 No recent reports of development identified after preregistration for Acne (Treatment-resistant) in European Union (PO)
  • 27 Jan 2017 The Committee for Medicinal Products for Human Use (CHMP) adopts positive opinion for estradiol valerate/dienogest for Acne (treatment-resistant) in European Union
  • 31 Dec 2016 Preregistration for Acne (Treatment-resistant) in European Union (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top